SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (8252)1/8/1999 6:53:00 PM
From: aknahow  Read Replies (1) of 17367
 
The two biggest problem, IMO are financing and the FDA insistence on evaluating efficacy. Floorless convertible pfds. can be killers but so is not having the capital required to remain in business. Billions of dollars of herbal, "drugs", are sold to the public without any FGA review. Of course they make no claims.

I would rather trust my ability to read about a new drug and my doctors input rather than be prevented access to drugs, my doctors thought would do some good. Instead since this might be abused the U.S. has chosen to regulate more than just safety, creating jobs for people that like to regulate the decisions of others, if they live long enough to decide for themselves. These are not XOMA's views. XOMA loves the FDA and believes 100% in the present
system.

The two problems are linked as the greater the cost the more capital needs to be raised. Aside from these problems biotechnology should be a great area for "investment". The point of all this is that this is a very difficult field to invest in.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News